Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Human ErbB2/Her2 (Research Grade Trastuzumab Biosimilar) Alexa Fluor 700-conjugated Antibody, R&D Systems™
Human Monoclonal Antibody
Supplier: R&D Systems FAB9589N100UG
This item is not returnable.
View return policy
Description
ErbB2/Her2 Monoclonal specifically detects ErbB2/Her2 in Human samples. It is validated for Flow Cytometry.Specifications
ErbB2/Her2 | |
Monoclonal | |
Alexa Fluor 700 | |
Supplied in a saline solution containing BSA and Sodium Azide. | |
Human | |
Protein A or G purified from cell culture supernatant | |
Primary | |
Detects human ErbB2/Her2 in direct ELISAs. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Trastuzumab. This product is for research use only. | |
Human | |
Supernatant |
Flow Cytometry | |
Hu5 | |
Flow Cytometry 0.25-1 ug/10^6 cells | |
CD340, CD340 antigen, c-erb B2/neu protein, EC 2.7.10, EGFR2, HER2, HER-2, HER2EC 2.7.10.1, herstatin, Metastatic lymph node gene 19 protein, MLN 19, MLN19, Neu Oncogene, NEUHER-2/neu, neuroblastoma/glioblastoma derived oncogene homolog, NGL, NGLTKR1, p185erbB2, Proto-oncogene c-ErbB-2, Proto-oncogene Neu, receptor tyrosine-protein kinase erbB-2, TKR1, Tyrosine kinase-type cell surface receptor HER2, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2(neuro/glioblastoma derived oncogene homolog), v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastomaderived oncogene homolog (avian) | |
Human ErbB2/Her2 | |
100 μg | |
2064 | |
Reconstitution default not known | |
Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 degreesC as supplied. | |
IgG1 |
Provide Content Correction
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?
Provide Content Correction